Clinical trials
Platinum-resistant Recurrent Ovarian Cancer clinical trials
Below are recruiting platinum-resistant recurrent ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 58 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Mobile, AlabamaAges 18 years+ - NCT07489287RecruitingPhase 1
GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
Buffalo, New YorkAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT06618235RecruitingPhase 1/Phase 2
Testing the virus therapy THEO-260 for ovarian cancer
This trial tests a new virus-based medicine called THEO-260 for people with a certain type of ovarian cancer that no longer responds to standard platinum chemo. The goal is to see if this treatment can shrink tumors or slow the cancer down.
MadridAges 18 years+ - NCT07211659RecruitingPhase 1
THEO-260 injection for ovarian cancer patients
This trial tests an investigational drug called THEO-260, given directly into the belly (intraperitoneal), for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and effective.
Houston, TexasAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Birmingham, AlabamaAges 18 years+ - NCT06617923RecruitingPhase 2
Senaparib and Temozolomide for ARID1A-Mutated Ovarian Cancer
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Baltimore, MarylandAges 18 years+ - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT06540729RecruitingPhase 2
RC48, AK104, and Bevacizumab for Ovarian Clear Cell Cancer
This trial tests a combination of three drugs: RC48 (targets HER2), AK104 (a PD-1/CTLA-4 blocker), and bevacizumab (a blood vessel growth blocker) for ovarian clear cell carcinoma. It may be an option for women whose tumors have low levels of HER2 and who have not had immunotherapy before, after up to two prior chemotherapies.
Guanzhou, GuangdongAges 18–75
Hear when a new Platinum-resistant Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for platinum-resistant recurrent ovarian cancer?
- Yes. Clin2 currently lists 58 recruiting platinum-resistant recurrent ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a platinum-resistant recurrent ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a platinum-resistant recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.